Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. (Nasdaq: IMNM) is a clinical-stage targeted oncology company whose news flow is closely tied to the progress of its cancer drug pipeline and capital markets activity. Press releases and updates frequently describe advances in its lead programs, including varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, and IM-1021, a ROR1-targeted antibody-drug conjugate (ADC) that uses the company’s proprietary HC74 TOP1 inhibitor payload.
Investors following IMNM news can expect detailed announcements on clinical trial milestones, such as topline data from the global Phase 3 RINGSIDE trial of varegacestat, which met its primary and key secondary endpoints in patients with progressing desmoid tumors. Immunome also issues updates on early clinical activity for IM-1021 in B-cell lymphoma, IND clearance for the FAP-targeted radioligand IM-3050, and progress across its preclinical ADC programs IM-1617, IM-1335 and IM-1340.
In addition to R&D updates, Immunome regularly reports financial and corporate developments. Recent news includes quarterly financial results, guidance on cash runway, and details of a follow-on public offering of common stock under an effective shelf registration statement. The company also discloses inducement stock option grants under its 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), as well as participation in major healthcare and investor conferences.
This IMNM news page aggregates these disclosures so readers can track trial readouts, regulatory plans such as the intended NDA submission for varegacestat, financing transactions, and corporate presentations in one place. For investors, analysts and healthcare professionals, the stream of Immunome news provides insight into the evolution of its targeted oncology pipeline and its use of capital to support ongoing development.
Immunome (Nasdaq: IMNM), a biotechnology company developing targeted cancer therapies, has announced the granting of inducement awards to five new employees. The awards, approved by the Compensation Committee on April 1, 2025, consist of non-statutory stock options to purchase a total of 228,000 shares of common stock under the company's 2024 Inducement Plan.
The stock options have an exercise price of $6.26 per share, matching Immunome's closing price on April 1, 2025. These options will vest over a four-year period, with 25% vesting after one year and the remaining balance vesting monthly over the subsequent 36 months, contingent on continued employment.
Immunome (NASDAQ: IMNM) announced its full year 2024 financial results and business updates. The company expects topline data from the Phase 3 RINGSIDE study of varegacestat for desmoid tumors in H2 2025. Key developments include the first patient dosing in Phase 1 trial of IM-1021 (ROR1-targeted ADC) and IND submission for IM-3050 (FAP-targeted radioligand therapy).
Financial highlights: Cash position of $217.3 million as of December 31, 2024, plus additional $172.5 million from January 2025 financing. The company reported R&D expenses of $129.5M, in-process R&D expenses of $152.3M, and G&A expenses of $33.0M for 2024. Net loss was $293.0M. Cash runway extends into 2027.
Pipeline progress includes three novel ADCs (IM-1617, IM-1340, IM-1335) in IND-enabling manufacturing and completion of RINGSIDE Part B enrollment in February 2024.
Immunome (NASDAQ: IMNM) has initiated patient dosing in its Phase 1 clinical trial of IM-1021, a ROR1-targeted ADC (Antibody-Drug Conjugate). The first-in-human trial is designed as an open-label, multicenter study focusing on dose escalation and expansion to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of IM-1021.
The study will include patients with advanced B-cell lymphomas and advanced solid tumors. IM-1021 is an optimized ADC incorporating Immunome's proprietary TOP1 inhibitor, HC74, targeting patients with high unmet medical needs.
Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The company's Compensation Committee approved non-statutory stock options for 49,000 shares of common stock to four new employees under its 2024 Inducement Plan.
The stock options were granted on March 3, 2025, with an exercise price of $8.94 per share, matching the company's closing price on that date. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months, contingent on continued employment.
Immunome (Nasdaq: IMNM), a biotechnology company developing first-in-class and best-in-class targeted cancer therapies, has announced its participation in two major investor conferences in March 2025.
The company will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 1:10 p.m. ET. The conference runs from March 3-5, 2025.
Additionally, Immunome will participate in the Leerink Partners Global Healthcare Conference 2025 on March 10, 2025, at 1:40 p.m. ET. This conference is scheduled for March 10-12, 2025.
Live webcast links for both presentations will be available on the events tab of Immunome's investor website, with replay links accessible for 30 days following the live broadcasts.
Aro Biotherapeutics announced a leadership transition as co-founder Susan Dillon, Ph.D., steps down from her position as president and CEO to continue as chair of the Board of Directors. The company has appointed Purnanand Sarma, Ph.D. as the new CEO and board member, effective immediately.
Dr. Sarma brings over three decades of pharmaceutical experience and will lead the development of Aro's pipeline of siRNA-conjugate medications, including ABX1100, a novel Centyrin-GYS1 siRNA drug conjugate for Pompe disease treatment. His background includes extensive drug development experience and success in IPOs, M&A, and company transactions, most recently serving as CEO of Immunome.
The transition comes as Aro advances its mission to develop targeted short-interfering RNA (siRNA) medicines, with its lead program already in clinical testing. The company's focus remains on creating a new class of targeted siRNA medicines for intractable diseases using their proprietary Centyrin technology.
Immunome (NASDAQ: IMNM) announced that its Compensation Committee granted inducement awards to four new employees on February 3, 2025. The awards consist of non-statutory stock options to purchase a total of 51,000 shares of common stock under the Company's 2024 Inducement Plan.
The stock options have an exercise price of $10.32 per share, matching the Company's closing price on February 3, 2025. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over the following 36 months, contingent on continued employment. These grants were approved as inducement material for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Immunome (NASDAQ: IMNM) has successfully closed its upsized public offering, selling 22,258,064 shares of common stock at $7.75 per share, including the full exercise of underwriters' option to purchase an additional 2,903,225 shares. The offering generated gross proceeds of $172.5 million before deducting underwriting discounts, commissions, and expenses.
The offering was managed by multiple financial institutions, with J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities acting as joint book-running managers, while Wedbush PacGrow served as lead manager. The offering was conducted under a shelf registration statement on Form S-3 filed with the SEC on February 13, 2024.
Immunome (Nasdaq: IMNM) has announced the pricing of an upsized public offering of 19,354,839 shares of common stock at $7.75 per share. The company expects to raise gross proceeds of $150.0 million before deducting underwriting discounts and expenses.
The offering includes a 30-day option for underwriters to purchase up to an additional 2,903,225 shares at the public offering price. The offering is expected to close on January 31, 2025. J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities are acting as joint book-running managers, with Wedbush PacGrow as lead manager.
Immunome (NASDAQ: IMNM) has announced plans for an underwritten public offering of $125.0 million worth of common stock shares. The biotechnology company, focused on developing first-in-class and best-in-class targeted cancer therapies, will grant underwriters a 30-day option to purchase up to an additional 15% of the shares sold in the offering.
The offering will be managed by joint book-running managers J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities, with Wedbush PacGrow acting as lead manager. The offering is being made through a shelf registration statement on Form S-3 filed with the SEC on February 13, 2024.